In turn, in a study conducted by Lin et al. [46] on colon cancer cells (DLD-1 and LoVo), bergapten treatment triggered p53-mediated biochemical events associated with cycle blockage in the G0/G1 phase and cellular apoptosis. The gene discussed is TP53; the disease is colonic neoplasm.